Ir para o conteúdo principal

United StatesÚltimas notícias

Grafa

Denali Therapeutics achieves landmark FDA approval for first brain-penetrant Hunter Syndrome therapy

Denali Therapeutics (NASDAQ:DNLI), a biopharmaceutical company dedicated to developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB), announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm).

Leia mais